Polypseudorotaxane formation of randomly-pegylated insulin with cyclodextrins: slow release and resistance to enzymatic degradation

Chem Pharm Bull (Tokyo). 2009 May;57(5):541-4. doi: 10.1248/cpb.57.541.

Abstract

Pegylation technology has been widely used to improve therapeutic efficacies of protein drugs and a number of selective- or randomly-substituted pegylated proteins are on the market. In this study, we prepared a insulin derivative substituted randomly with poly(ethylene glycol) (PEG, MW about 2200) and its polypseudorotaxanes with cyclodextrins (CyDs). The pegylated insulin formed polypseudorotaxanes with alpha- and gamma-CyDs, by inserting one PEG chain in the alpha-CyD cavity and two PEG chains in the gamma-CyD cavity. The pegylated insulin/CyD polypseudorotaxanes were less soluble in water. The release rate of the pegylated protein from its polypseudorotaxanes decreased in the order of drug alone>the gamma-CyD polypseudorotaxane>the alpha-CyD polypseudorotaxane. The pegylated insulin/gamma-CyD polypseudorotaxane displayed a significantly higher resistance to proteolysis. The results indicated that the CyD polypseudorotaxanes could be formed with randomly-pegylated insulin and work not only as a sustained release system, but also as a stabilizing agent to enzymatic degradations of pegylated insulin.

MeSH terms

  • Cyclodextrins / chemistry*
  • Delayed-Action Preparations / pharmacology
  • Drug Carriers / chemistry*
  • Drug Delivery Systems
  • Drug Stability
  • Enzyme Activation / drug effects
  • Hypoglycemic Agents / pharmacology*
  • Insulin / chemistry*
  • Polyethylene Glycols / chemistry*
  • Polymers / chemistry*
  • Rotaxanes / chemistry*
  • Surface Properties

Substances

  • Cyclodextrins
  • Delayed-Action Preparations
  • Drug Carriers
  • Hypoglycemic Agents
  • Insulin
  • Polymers
  • Rotaxanes
  • Polyethylene Glycols